🧬 New insights into EBV and multiple sclerosis (MS)
EBV-MS researchers found that MS is linked to stronger EBV-specific immune responses, reduced by anti-CD20 therapy. The findings support future EBV-targeted vaccines and antiviral approaches.
Read the paper: buff.ly/LOEmoR0
buff.ly
CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis
CD4+ T cells in MS preferentially recognize EBV viral particles rather than latent antigens, and responses are reduced by B cell–targeting therapies.